Trimethobenzamide Hydrochloride — Active Pharmaceutical Ingredient

Trimethobenzamide Hydrochloride is an active pharmaceutical ingredient found in 3 FDA-approved drug products. Forms: INJECTABLE, CAPSULE. Routes: INJECTION, ORAL.

This content is for informational purposes only. Always consult a healthcare professional.

Trimethobenzamide Hydrochloride (3 brand names, 2 dosage forms, 2 routes)

Available dosage forms: INJECTABLE, CAPSULE.

Routes of administration: INJECTION, ORAL.

Brand Names

  • TIGAN
  • TRIMETHOBENZAMIDE HYDROCHLORIDE
  • TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

Indications and Usage

Trimethobenzamide Hydrochloride Injection is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.

Dosage and Administration

(See WARNINGS and PRECAUTIONS .) Dosage should be adjusted according to the indication for therapy, severity of symptoms and the response of the patient.

Contraindications

Trimethobenzamide Hydrochloride Injection is contraindicated in pediatric patients and in patients with known hypersensitivity to trimethobenzamide.

Adverse Reactions

There have been reports of hypersensitivity reactions and Parkinson-like symptoms. There have been instances of hypotension reported following parenteral administration to surgical patients. There have been reports of blood dyscrasias, blurring of vision, coma, convulsions, depression of mood, diarrhea, disorientation, dizziness, drowsiness, headache, jaundice, muscle cramps and opisthotonos. If these occur, the administration of the drug should be discontinued. Allergic-type skin reactions have been observed; therefore, the drug should be discontinued at the first sign of sensitization. While these symptoms will usually disappear spontaneously, symptomatic treatment may be indicated in some cases. For medical advice about adverse reactions contact your medical professional. To report SUSPECTED ADVERSE REACTIONS, contact BPI Labs, LLC at (727) 471-0850 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Mechanism of Action

The mechanism of action of Trimethobenzamide Hydrochloride Injection as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited. In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.